Revelation Pharma Acquires Cascade Specialty Pharmacy, Enhancing Focus on Animal Health and Compounding

Revelation Pharma Strengthens Its Position in Compounding Pharmacy with Cascade Acquisition

Revelation Pharma, a leading national network of 503A and 503B compounding pharmacies, has made a significant move by acquiring Cascade Specialty Pharmacy, located in Washington. This strategic acquisition enhances Revelation Pharma's presence in the western and northwestern regions, including California, and underscores its commitment to excellence in the compounding pharmacy sector, particularly in Ear, Nose, and Throat (ENT) and Animal Health formulations. CEO Shawn Hodges has articulated that this partnership aligns perfectly with the company's mission of upholding high standards in patient care, a critical focus in an industry increasingly dedicated to personalized health solutions.

The acquisition allows Cascade Specialty Pharmacy to maintain its operations at its current location, ensuring that existing customers continue to have access to familiar services while benefiting from an expanded array of product offerings. Among these is the well-regarded CSalts—a line of medicated salt packets designed to facilitate sinus irrigation. This addition not only broadens the pharmacy's product range but also enhances the overall service capabilities of the network, ultimately aiming to deliver better health outcomes for patients in both human and animal sectors. Former owner Brandon Knott has expressed optimism about the transition, confident that Revelation Pharma’s resources and expertise will propel Cascade’s mission forward, while he remains involved as an ENT Allergy Product Specialist.

Angela Williams, the Pharmacist In Charge at Cascade, has also highlighted the excitement surrounding this collaboration, recognizing the potential for growth and innovation within the compounding pharmacy landscape. Revelation Pharma’s extensive footprint across all 50 states, coupled with its offerings such as virtual telemedicine, positions it well to provide quality, personalized pharmaceutical preparations. This acquisition not only reflects a strategic enhancement of their capabilities but also a commitment to addressing the evolving needs of communities nationwide.

In a parallel development, Phibro Animal Health Corporation is preparing to release its second quarter financial results on February 5, 2025. The management team will host a conference call the following day to discuss these results, emphasizing the company's commitment to innovation and improving animal health outcomes. As Phibro gears up for this financial update, it reinforces its mission to be a reliable partner for livestock producers, veterinarians, and pet owners, showcasing its dedication to enhancing the well-being of both farm and companion animals.

As the animal health and pharmaceutical sectors continue to evolve, strategic acquisitions like Revelation Pharma's serve as a reminder of the importance of adaptability and innovation in meeting the needs of diverse customer bases.